– UK, London – SpectrumX, UK-based healthcare, and pharmaceutical company, today announced the upcoming appointment of Aziz McMahon to its Board of Directors as Executive Chairman, focusing on investor relations, corporate governance, and the formulation of the new ESG policy.
SpectrumX is currently closing in on final pre-IPO capital raising ahead of its planned listing on the London Stock Exchange, in Q4 2021.
“As an early-stage cornerstone investor, Aziz has been a key team member and advisor since our inception. We are delighted he has agreed to this appointment, where he will focus his abilities and wealth of experience on the development of our group as we enter this exciting new phase ahead of our listing. Aziz believes – as I do – that we truly are on the cusp of one of the most revolutionary treatments since the discovery of penicillin, and that passion combined with his expertise makes him the ideal person for such an important role.” said CEO and Co-Founder, Damien Hancox.
About Aziz McMahon
A finance professional, angel, and early-stage cornerstone investor in SpectrumX, Aziz McMahon brings over 20 years of experience in investment banking. He spent the previous 14 years as a Managing Director, Emerging Markets, at Goldman Sachs. His other interests include early-stage biotech, environmental regeneration, and digital assets. McMahon also runs a mentorship program to promote racial, gender and socio-economic diversity in finance.
Aziz McMahon said: “Having supported SpectrumX since the outset, I am excited to agree to an executive chairman role, as the company accelerates the development and deployment of its patented chemistry, a 100-percent safe and effective nature-based cure to all pathogens known to mankind. I look forward to ensuring the company continues its path of success as it becomes a public company, adhering to strict ESG standards, including carbon neutrality, transparent investor relations, and the highest standards in corporate governance.”
SpectrumX is a UK-based healthcare and pharmaceuticals company focused on bringing to market a ground-breaking respiratory therapy and the rollout of the most powerful hand sanitizer in the world to the NHS and other healthcare clients. Both products utilize unique patent-pending HOCL formulations. HOCL is naturally occurring in human white blood cells and is a key contributor to mankind’s evolution and protection over millions of years. It is human safe whilst also being the most effective disinfectant known to mankind.
For more information: https://spectrumx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.